PL3233103T3 - Leczenie pęcherzycy - Google Patents
Leczenie pęcherzycyInfo
- Publication number
- PL3233103T3 PL3233103T3 PL15823107T PL15823107T PL3233103T3 PL 3233103 T3 PL3233103 T3 PL 3233103T3 PL 15823107 T PL15823107 T PL 15823107T PL 15823107 T PL15823107 T PL 15823107T PL 3233103 T3 PL3233103 T3 PL 3233103T3
- Authority
- PL
- Poland
- Prior art keywords
- pemphigus
- treatment
- Prior art date
Links
- 241000721454 Pemphigus Species 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462093891P | 2014-12-18 | 2014-12-18 | |
| EP15823107.6A EP3233103B1 (en) | 2014-12-18 | 2015-12-18 | Treatment of pemphigus |
| PCT/US2015/066868 WO2016100914A1 (en) | 2014-12-18 | 2015-12-18 | Treatment of pemphigus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3233103T3 true PL3233103T3 (pl) | 2021-04-19 |
Family
ID=55080225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15823107T PL3233103T3 (pl) | 2014-12-18 | 2015-12-18 | Leczenie pęcherzycy |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10485797B2 (pl) |
| EP (1) | EP3233103B1 (pl) |
| CN (1) | CN107257686B (pl) |
| AU (2) | AU2015364335B2 (pl) |
| CA (1) | CA2970723C (pl) |
| EA (1) | EA036269B1 (pl) |
| ES (1) | ES2843323T3 (pl) |
| IL (1) | IL252839B (pl) |
| MA (1) | MA41197B1 (pl) |
| MX (1) | MX381283B (pl) |
| PL (1) | PL3233103T3 (pl) |
| PT (1) | PT3233103T (pl) |
| SG (1) | SG11201704808VA (pl) |
| WO (1) | WO2016100914A1 (pl) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900344T1 (it) | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| PL2989106T3 (pl) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
| US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| IL293319B1 (en) | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| CN110087680B (zh) * | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| SI3555099T1 (sl) * | 2016-12-15 | 2021-11-30 | F. Hoffmann-La Roche Ag | Postopek priprave zaviralcev BTK |
| CN108329274B (zh) * | 2017-01-13 | 2021-09-03 | 正大天晴药业集团股份有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
| EP3573989A4 (en) * | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| CN108727404B (zh) * | 2017-04-14 | 2020-05-12 | 中国科学院上海药物研究所 | 噻吩并[3,2-d]嘧啶类化合物、其制备方法及用途 |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| US20210113568A1 (en) * | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
| WO2020057549A1 (en) * | 2018-09-18 | 2020-03-26 | Beijing Innocare Pharma Tech Co., Ltd. | Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide |
| SG11202103861YA (en) * | 2018-11-06 | 2021-05-28 | Beijing Innocare Pharma Tech Co Ltd | Amorphous solid dispersion comprising 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide |
| CN109939223B (zh) * | 2019-04-04 | 2020-04-07 | 中南大学湘雅二医院 | 一种白介素2在制备用于治疗寻常型天疱疮口腔糜烂药物的应用 |
| EP3981399A4 (en) | 2019-06-10 | 2023-05-31 | BeiGene Switzerland GmbH | ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF |
| CN115190798A (zh) | 2019-10-09 | 2022-10-14 | 普林斯匹亚生物制药公司 | 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗天疱疮的方法 |
| AU2020365951B2 (en) | 2019-10-14 | 2026-07-16 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| KR102993352B1 (ko) | 2019-12-20 | 2026-07-22 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태 |
| CA3163850A1 (en) * | 2020-01-08 | 2021-07-15 | Principia Biopharma Inc. | Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile |
| WO2021150723A1 (en) | 2020-01-22 | 2021-07-29 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| WO2021207662A1 (en) * | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
| EP4322957A1 (en) * | 2021-04-16 | 2024-02-21 | Principia Biopharma Inc. | Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| EP4611755A1 (en) | 2022-10-31 | 2025-09-10 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-l-yl]pent-2-enenitrile |
| WO2024124113A1 (en) | 2022-12-09 | 2024-06-13 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia in subjects with cognitive impairment by administering rilzabrutinib |
| CN116849178A (zh) * | 2023-06-26 | 2023-10-10 | 武汉大学中南医院 | 胎源性成年骨关节炎易感模型的构建方法、共性干预靶标及其应用 |
| AU2024306785A1 (en) | 2023-06-30 | 2026-02-19 | Principia Biopharma Inc. | Methods for treating persistent or chronic immune thrombocytopenia in children, adolescents and adults by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4- methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| AU2024292378A1 (en) | 2023-07-17 | 2026-03-05 | Kadmon Corporation, Llc | Combination therapy comprising btk inhibitor and belumosudil |
| CN122094692A (zh) | 2023-10-25 | 2026-05-26 | 普林斯匹亚生物制药公司 | 用于治疗与特应性皮炎和/或结节性痒疹相关的搔痒的瑞扎布鲁替尼 |
| AU2024394777A1 (en) | 2023-12-06 | 2026-07-23 | Principia Biopharma Inc. | Treatment of moderate-to-severe asthma by administering rilzabrutinib |
| WO2026024765A1 (en) | 2024-07-23 | 2026-01-29 | Principia Biopharma Inc. | Treatment of venous thrombosis with rilzabrutinib and derivatives thereof |
| WO2026024885A1 (en) | 2024-07-24 | 2026-01-29 | Principia Biopharma Inc. | Rilzabrutinib for treating warm antibody autoimmune hemolytic anemia |
| WO2026035812A1 (en) | 2024-08-08 | 2026-02-12 | Principia Biopharma Inc. | Methods for treating sickle cell disease by administering a btk inhibitor |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082819A (en) | 1977-03-02 | 1978-04-04 | The Standard Oil Company | Rubber-modified acrylonitrile-vinyl ether-indene polymers |
| JPS5663950A (en) | 1979-10-30 | 1981-05-30 | Mitsubishi Chem Ind Ltd | Cyclopropanecarboxylic ester |
| FR2535721A1 (fr) | 1982-11-08 | 1984-05-11 | Sanofi Sa | Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| JPS623848A (ja) | 1985-06-28 | 1987-01-09 | Nippon Steel Corp | 疲労強度のすぐれたスタツド付きフラツシユバツト溶接アンカ−チエ−ン |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2518353B2 (ja) | 1988-06-09 | 1996-07-24 | 住友化学工業株式会社 | シアノ酢酸アミド誘導体およびその製造中間体 |
| CA2018801C (en) | 1990-06-12 | 2000-08-22 | Pierre Louis Beaulieu | Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus |
| JPH04177244A (ja) | 1990-11-10 | 1992-06-24 | Konica Corp | ハロゲン化銀写真感光材料 |
| CA2033447C (en) | 1990-12-31 | 1999-08-31 | Robert Deziel | Synergistic combination for treating herpes infections |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JPH05301838A (ja) | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
| US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| JPH0827090A (ja) | 1994-05-13 | 1996-01-30 | Sumitomo Chem Co Ltd | シアノ酢酸アミド誘導体、その用途およびその製造中間体 |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| PL335839A1 (en) | 1997-03-14 | 2000-05-22 | Basf Ag | Cycloalkylalkane carboxamides as well as their production and application |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| IL125947A0 (en) | 1997-09-17 | 1999-04-11 | American Cyanamid Co | 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents |
| DE69814122T2 (de) | 1997-10-09 | 2004-03-18 | Dexcel Pharma Technologies Ltd. | Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| CA2366932C (en) | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| KR20020088406A (ko) | 1999-09-17 | 2002-11-27 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 피라졸로피리미딘 |
| AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| WO2003037890A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
| JP3991812B2 (ja) | 2001-12-11 | 2007-10-17 | 住友化学株式会社 | エステル化合物およびその用途 |
| AU2003210983A1 (en) | 2002-02-11 | 2003-09-04 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
| NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
| GB0219024D0 (en) | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| JP2006518368A (ja) | 2003-02-21 | 2006-08-10 | ファイザー・インク | プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体 |
| WO2004100868A2 (en) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
| JP4727579B2 (ja) | 2003-08-01 | 2011-07-20 | 中外製薬株式会社 | マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なシアノアミド化合物 |
| KR20060115350A (ko) | 2003-09-02 | 2006-11-08 | 화이자 프로덕츠 인크. | 지프라시돈의 지속 방출형 투여 형태 |
| WO2005023773A1 (en) | 2003-09-04 | 2005-03-17 | Pfizer Limited | Process for the preparation of substituted aryl pyrazoles |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| BRPI0414798A (pt) | 2003-09-25 | 2006-11-21 | Warner Lambert Co | métodos para usar aminoácidos com afinidade para a proteìna alfa2delta |
| WO2005074603A2 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| JP4552456B2 (ja) | 2004-02-27 | 2010-09-29 | 住友化学株式会社 | エステル化合物およびその用途 |
| EP1724264A1 (en) | 2004-03-10 | 2006-11-22 | Ono Pharmaceutical Co., Ltd. | Nitriles and medicinal compositions containing the same as the active ingredient |
| US7807719B2 (en) | 2004-09-14 | 2010-10-05 | Chaim Roifman | Compounds useful for modulating abnormal cell proliferation |
| US20060079494A1 (en) | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
| CA2597587A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
| US20080260818A1 (en) | 2005-03-28 | 2008-10-23 | Dexcel Pharma Technologies Ltd. | Controlled Absorption of Statins in the Intestine |
| EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| US20080176865A1 (en) | 2005-06-15 | 2008-07-24 | Pfizer Limited | Substituted arylpyrazoles |
| US7645786B2 (en) | 2005-06-15 | 2010-01-12 | Pfizer Inc. | Substituted arylpyrazoles |
| EP1893581B1 (en) | 2005-06-15 | 2010-01-27 | Pfizer Limited | Substituted arylpyrazoles for use against parasitites |
| US20070149464A1 (en) | 2005-06-15 | 2007-06-28 | Pfizer Inc. | Combination |
| US20080146643A1 (en) | 2005-06-15 | 2008-06-19 | Pfizer Limited | Combination |
| GB0517205D0 (en) | 2005-08-22 | 2005-09-28 | Novartis Ag | Organic compounds |
| CA2623327A1 (en) | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| JP5193876B2 (ja) | 2005-12-02 | 2013-05-08 | バイエル・ヘルスケア・エルエルシー | オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体 |
| KR20080098490A (ko) | 2006-01-13 | 2008-11-10 | 파마시클릭스, 인코포레이티드 | 티로신 키나제 억제제 및 이의 용도 |
| WO2007115269A2 (en) | 2006-03-31 | 2007-10-11 | The Board Of Regents Of The University Of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
| US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
| US8846697B2 (en) | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
| WO2008005954A2 (en) | 2006-06-30 | 2008-01-10 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| RU2481336C2 (ru) | 2006-07-06 | 2013-05-10 | Эррэй Биофарма Инк. | Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| WO2008054827A2 (en) | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| AU2007323335A1 (en) | 2006-11-23 | 2008-05-29 | Novartis Ag | Pyrimidines and their use as CXCR2 receptor antagonists |
| WO2008116064A2 (en) | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| GB2447933A (en) | 2007-03-27 | 2008-10-01 | Chemence Ltd | Cyanoacrylate monomer for forming an adhesive polymer |
| EP2139487B1 (en) | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| ATE522536T1 (de) | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
| RU2503676C2 (ru) | 2008-02-25 | 2014-01-10 | Ф.Хоффманн-Ля Рош Аг | Пирролопиразиновые ингибиторы киназы |
| CA2722418C (en) | 2008-05-13 | 2013-09-17 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| JP2011520986A (ja) | 2008-05-22 | 2011-07-21 | アムジエン・インコーポレーテツド | タンパク質キナーゼ阻害薬としての複素環類 |
| CN102159214A (zh) | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| RU2011105768A (ru) | 2008-08-01 | 2012-09-10 | Биокрист Фармасьютикалз, Инк. (Us) | Производные пиперидина в качестве ингибиторов jakз |
| US8450337B2 (en) | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
| US20100113520A1 (en) | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
| US20120028981A1 (en) | 2008-11-05 | 2012-02-02 | Principia Biopharma Inc. | Kinase Knockdown Via Electrophilically Enhanced Inhibitors |
| US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| KR20120063515A (ko) | 2009-09-09 | 2012-06-15 | 아빌라 테라퓨틱스, 인크. | Ｐｉ３ 키나제 억제제 및 이들의 용도 |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| CN102711765A (zh) | 2009-11-16 | 2012-10-03 | 加利福尼亚大学董事会 | 激酶抑制剂 |
| EP2571880A1 (en) | 2010-05-20 | 2013-03-27 | F.Hoffmann-La Roche Ag | Pyrrolo [2, 3 - b]pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors |
| US8940725B2 (en) | 2010-05-31 | 2015-01-27 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| CN101880243A (zh) | 2010-06-04 | 2010-11-10 | 贵阳柏丝特化工有限公司 | 一种含氟氰拟除虫菊酯化合物及其合成方法与用途 |
| PH12013500246A1 (en) | 2010-08-10 | 2019-10-11 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| WO2012158810A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| DK2710007T3 (da) | 2011-05-17 | 2020-01-27 | Principia Biopharma Inc | Kinasehæmmere |
| WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| AU2012255860C1 (en) | 2011-05-17 | 2015-12-10 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US8828426B2 (en) | 2011-06-07 | 2014-09-09 | Zx Pharma, Llc | Multiparticulate L-carnitine compositions and related methods |
| WO2013003629A2 (en) | 2011-06-28 | 2013-01-03 | Pharmacyclics, Inc. | Methods and compositions for inhibition of bone resorption |
| KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
| WO2013010869A1 (en) | 2011-07-19 | 2013-01-24 | Msd Oss B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| CN103889987B (zh) * | 2011-07-19 | 2016-09-14 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
| KR20140063700A (ko) | 2011-09-20 | 2014-05-27 | 셀좀 리미티드 | 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체 |
| US20140303191A1 (en) | 2011-10-19 | 2014-10-09 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| EP2858500A4 (en) | 2012-06-08 | 2016-04-06 | Biogen Ma Inc | BRUTON TYROSINE KINASE HEMMER |
| CN104487441B (zh) * | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
| WO2014004707A1 (en) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| US9572811B2 (en) | 2012-08-03 | 2017-02-21 | Principia Biopharma Inc. | Treatment of dry eye |
| SMT201900344T1 (it) | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| US20150291554A1 (en) | 2012-11-02 | 2015-10-15 | Pfizer Inc. | Bruton's Tyrosine Kinase Inhibitors |
| KR20150084923A (ko) | 2012-11-15 | 2015-07-22 | 파마시클릭스, 인코포레이티드 | 키나제 억제제로서의 피롤로피리미딘 화합물 |
| US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
| JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| SG11201605417QA (en) | 2014-02-03 | 2016-08-30 | Cadila Healthcare Ltd | Heterocyclic compounds |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
| CN107427468B (zh) | 2014-12-24 | 2022-02-25 | 普林斯匹亚生物制药公司 | Btk抑制剂的部位特异性给药 |
| HRP20230305T1 (hr) | 2014-12-24 | 2023-05-26 | Principia Biopharma Inc. | Pripravci za ileo-jejunalnu dostavu lijeka |
| EP3912979B1 (en) | 2015-06-03 | 2026-03-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| US10358446B2 (en) | 2015-10-14 | 2019-07-23 | Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. | Bruton's tyrosine kinase inhibitors |
| IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
-
2015
- 2015-12-18 SG SG11201704808VA patent/SG11201704808VA/en unknown
- 2015-12-18 MX MX2017007973A patent/MX381283B/es unknown
- 2015-12-18 EP EP15823107.6A patent/EP3233103B1/en active Active
- 2015-12-18 AU AU2015364335A patent/AU2015364335B2/en active Active
- 2015-12-18 ES ES15823107T patent/ES2843323T3/es active Active
- 2015-12-18 PT PT158231076T patent/PT3233103T/pt unknown
- 2015-12-18 PL PL15823107T patent/PL3233103T3/pl unknown
- 2015-12-18 CN CN201580076193.1A patent/CN107257686B/zh active Active
- 2015-12-18 US US15/537,294 patent/US10485797B2/en active Active
- 2015-12-18 EA EA201791243A patent/EA036269B1/ru not_active IP Right Cessation
- 2015-12-18 WO PCT/US2015/066868 patent/WO2016100914A1/en not_active Ceased
- 2015-12-18 CA CA2970723A patent/CA2970723C/en active Active
- 2015-12-18 MA MA41197A patent/MA41197B1/fr unknown
-
2017
- 2017-06-12 IL IL252839A patent/IL252839B/en active IP Right Grant
-
2019
- 2019-10-04 US US16/593,352 patent/US10946008B2/en active Active
-
2020
- 2020-11-05 AU AU2020264338A patent/AU2020264338A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017013022A2 (pt) | 2018-02-27 |
| SG11201704808VA (en) | 2017-07-28 |
| US20180050027A1 (en) | 2018-02-22 |
| AU2015364335B2 (en) | 2020-11-26 |
| IL252839B (en) | 2021-03-25 |
| US20200101059A1 (en) | 2020-04-02 |
| EP3233103A1 (en) | 2017-10-25 |
| CN107257686A (zh) | 2017-10-17 |
| EP3233103B1 (en) | 2020-10-14 |
| CN107257686B (zh) | 2021-01-29 |
| US10485797B2 (en) | 2019-11-26 |
| CA2970723A1 (en) | 2016-06-23 |
| MX381283B (es) | 2025-03-12 |
| AU2020264338A1 (en) | 2020-12-03 |
| IL252839A0 (en) | 2017-08-31 |
| MA41197B1 (fr) | 2021-01-29 |
| EA036269B1 (ru) | 2020-10-21 |
| MX2017007973A (es) | 2018-02-09 |
| CA2970723C (en) | 2023-09-05 |
| ES2843323T3 (es) | 2021-07-16 |
| WO2016100914A1 (en) | 2016-06-23 |
| US10946008B2 (en) | 2021-03-16 |
| AU2015364335A1 (en) | 2017-07-20 |
| PT3233103T (pt) | 2021-01-18 |
| EA201791243A1 (ru) | 2017-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252839A0 (en) | Treatment of boils | |
| GB201701673D0 (en) | Methods of well treatment | |
| PL3851537T3 (pl) | Leczenie hiperbilirubinemii | |
| IL285003A (en) | Treatment of episode disorders | |
| IL248856A0 (en) | New treatment | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| GB201410116D0 (en) | Method of treatment | |
| IL246880A0 (en) | Tumor treatment | |
| IL253028A0 (en) | treatment method | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201408297D0 (en) | Treatment of cancer | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201411027D0 (en) | Treatment | |
| GB201412411D0 (en) | Treatment | |
| GB201417456D0 (en) | Treatment of cancer | |
| GB201413317D0 (en) | Atheroscierosis treatment | |
| GB201412410D0 (en) | Treatment | |
| GB201400240D0 (en) | Treatment | |
| GB201400239D0 (en) | Treatment | |
| GB201400241D0 (en) | Treatment | |
| GB201400238D0 (en) | Treatment | |
| GB201400235D0 (en) | Treatment | |
| GB201417719D0 (en) | New treatment | |
| GB201408384D0 (en) | New treatment | |
| PT3851537T (pt) | Tratamento da hiperbilirrubinemia |